Dept. of Medicine, Section of Internal Medicine, University of Verona, Verona, Italy.
Haematologica. 2011 Jan;96(1):24-32. doi: 10.3324/haematol.2010.028506. Epub 2010 Sep 17.
Sickle cell disease, a genetic red cell disorder inherited in an autosomal recessive manner, occurs throughout the world. Hepatic dysfunction and liver damage may be present in sickle cell disease, but the pathogenesis of these conditions is only partially understood.
Transgenic mice with sickle cell disease (SAD mice) and wild-type mice were exposed to an ischemic/reperfusion stress. The following parameters were evaluated: hematologic profile, transaminase and bilirubin levels, liver histopathology, and mRNA levels of nuclear factor-κB p65, endothelial nitric oxide synthase, inducible nitric oxide synthase, heme oxygenase-1 and phosphodiesterase-1, -2, -3, and -4 genes in hepatocytes obtained by laser-capture microdissection. Immunoblotting was used to analyze the expression of the following proteins: nuclear factor-κB p65 and phospho-nuclear factor-κB p65, heme oxygenase-1, biliverdin reductase, heat shock protein-70, heat shock protein-27 and peroxiredoxin-6. A subgroup of SAD mice was treated with the phosphodiesterase-4 inhibitor rolipram (30 mg/Kg/day by gavage) during the ischemic/reperfusion protocol.
In SAD mice the ischemic/reperfusion stress induced liver damage compatible with sickle cell disease hepatopathy, which was associated with: (i) lack of hypoxia-induced nuclear factor-κB p65 activation; (ii) imbalance in the endothelial/inducible nitric oxide synthase response to ischemic/reperfusion stress; (iii) lack of hypoxia-induced increased expression of heme oxygenase-1/biliverdin reductase paralleled by a compensatory increased expression of heat shock proteins 70 and 27 and peroxiredoxin-6; and (iv) up-regulation of the phosphodiesterase-1, -2, -3, and -4 genes. In SAD mice the phosphodiesterase-4 inhibitor rolipram attenuated the ischemic/reperfusion-related microcirculatory dysfunction, reduced the inflammatory cell infiltration and induced the heme oxygenase-1/biliverdin reductase cytoprotective systems.
In SAD mice, sickle cell hepatopathy is associated with perturbed nuclear factor-κB p65 signaling with an imbalance of endothelial/inducible nitric oxide synthase levels, lack of heme oxygenase-1/biliverdin reductase expression and up-regulation of two novel cytoprotective systems: heat shock protein-27 and peroxiredoxin-6.
镰状细胞病是一种常染色体隐性遗传的红细胞遗传疾病,在世界各地都有发生。镰状细胞病可能会导致肝功能障碍和肝损伤,但这些病症的发病机制尚未完全阐明。
我们使用患有镰状细胞病的转基因小鼠(SAD 小鼠)和野生型小鼠进行了缺血/再灌注应激实验。评估了以下参数:血液学特征、转氨酶和胆红素水平、肝组织病理学、以及通过激光捕获显微切割获得的肝细胞中核因子-κB p65、内皮型一氧化氮合酶、诱导型一氧化氮合酶、血红素加氧酶-1 和磷酸二酯酶-1、-2、-3 和 -4 基因的 mRNA 水平。免疫印迹用于分析以下蛋白质的表达:核因子-κB p65 和磷酸化核因子-κB p65、血红素加氧酶-1、胆红素还原酶、热休克蛋白 70、热休克蛋白 27 和过氧化物还原酶 6。在缺血/再灌注方案期间,SAD 小鼠的一个亚组接受了磷酸二酯酶-4 抑制剂罗利普兰(通过灌胃每天 30mg/kg)治疗。
在 SAD 小鼠中,缺血/再灌注应激诱导的肝损伤与镰状细胞肝病相符,其特征为:(i)缺乏缺氧诱导的核因子-κB p65 激活;(ii)内皮型/诱导型一氧化氮合酶对缺血/再灌注应激的反应失衡;(iii)缺乏缺氧诱导的血红素加氧酶-1/胆红素还原酶表达增加,同时热休克蛋白 70 和 27 及过氧化物还原酶 6 的代偿性表达增加;以及(iv)磷酸二酯酶-1、-2、-3 和 -4 基因的上调。在 SAD 小鼠中,磷酸二酯酶-4 抑制剂罗利普兰可减轻缺血/再灌注相关的微循环功能障碍,减少炎症细胞浸润,并诱导血红素加氧酶-1/胆红素还原酶细胞保护系统。
在 SAD 小鼠中,镰状细胞肝病与核因子-κB p65 信号转导紊乱有关,伴有内皮型/诱导型一氧化氮合酶水平失衡、血红素加氧酶-1/胆红素还原酶表达缺失以及两种新的细胞保护系统:热休克蛋白 27 和过氧化物还原酶 6 的上调。